vs
Side-by-side financial comparison of FTAI Infrastructure Inc. (FIP) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($346.4M vs $188.4M, roughly 1.8× FTAI Infrastructure Inc.). HAEMONETICS CORP runs the higher net margin — 28.1% vs -79.7%, a 107.8% gap on every dollar of revenue. On growth, FTAI Infrastructure Inc. posted the faster year-over-year revenue change (95.9% vs 4.8%). Over the past eight quarters, FTAI Infrastructure Inc.'s revenue compounded faster (49.0% CAGR vs 1.5%).
FTAI Infrastructure Inc. owns, operates and invests in high-quality critical infrastructure assets across core sectors including transportation logistics, midstream energy, and power generation. It primarily serves North American markets, focusing on assets with stable long-term cash flows, contracted revenue streams, and strong market positions to deliver sustainable returns for stakeholders.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
FIP vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $188.4M | $346.4M |
| Net Profit | $-150.2M | $97.3M |
| Gross Margin | — | 57.2% |
| Operating Margin | — | 36.1% |
| Net Margin | -79.7% | 28.1% |
| Revenue YoY | 95.9% | 4.8% |
| Net Profit YoY | -387.6% | — |
| EPS (diluted) | $-1.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $188.4M | $346.4M | ||
| Q4 25 | $143.5M | $339.0M | ||
| Q3 25 | $140.6M | $327.3M | ||
| Q2 25 | $122.3M | $321.4M | ||
| Q1 25 | $96.2M | $330.6M | ||
| Q4 24 | $80.8M | $348.5M | ||
| Q3 24 | $83.3M | $345.5M | ||
| Q2 24 | $84.9M | $336.2M |
| Q1 26 | $-150.2M | $97.3M | ||
| Q4 25 | $-97.7M | $44.7M | ||
| Q3 25 | $-104.5M | $38.7M | ||
| Q2 25 | $-70.0M | $34.0M | ||
| Q1 25 | $120.2M | $58.0M | ||
| Q4 24 | $-124.7M | $37.5M | ||
| Q3 24 | $-43.0M | $33.8M | ||
| Q2 24 | $-48.1M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | -45.7% | 19.9% | ||
| Q3 25 | -70.8% | 17.9% | ||
| Q2 25 | -56.4% | 16.8% | ||
| Q1 25 | 81.8% | 21.6% | ||
| Q4 24 | -152.7% | 16.9% | ||
| Q3 24 | -51.7% | 15.0% | ||
| Q2 24 | -56.4% | 11.8% |
| Q1 26 | -79.7% | 28.1% | ||
| Q4 25 | -68.1% | 13.2% | ||
| Q3 25 | -74.4% | 11.8% | ||
| Q2 25 | -57.2% | 10.6% | ||
| Q1 25 | 125.0% | 17.5% | ||
| Q4 24 | -154.4% | 10.8% | ||
| Q3 24 | -51.6% | 9.8% | ||
| Q2 24 | -56.7% | 11.4% |
| Q1 26 | $-1.32 | — | ||
| Q4 25 | $-1.04 | $0.95 | ||
| Q3 25 | $-1.38 | $0.81 | ||
| Q2 25 | $-0.73 | $0.70 | ||
| Q1 25 | $0.89 | $1.17 | ||
| Q4 24 | $-1.21 | $0.74 | ||
| Q3 24 | $-0.45 | $0.66 | ||
| Q2 24 | $-0.52 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.9M | $245.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $-122.5K | $796.3M |
| Total Assets | $5.7B | $2.4B |
| Debt / EquityLower = less leverage | — | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $37.9M | $245.4M | ||
| Q4 25 | $57.4M | $363.4M | ||
| Q3 25 | $34.7M | $296.4M | ||
| Q2 25 | $33.6M | $292.9M | ||
| Q1 25 | $26.3M | $306.8M | ||
| Q4 24 | $27.8M | $320.8M | ||
| Q3 24 | $20.3M | $299.3M | ||
| Q2 24 | $33.1M | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $3.8B | $1.2B | ||
| Q3 25 | $3.7B | $1.2B | ||
| Q2 25 | $3.1B | $1.2B | ||
| Q1 25 | $2.8B | $1.2B | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.6B | — |
| Q1 26 | $-122.5K | $796.3M | ||
| Q4 25 | $21.3M | $911.5M | ||
| Q3 25 | $181.1M | $849.2M | ||
| Q2 25 | $375.5M | $882.3M | ||
| Q1 25 | $476.2M | $820.8M | ||
| Q4 24 | $202.7M | $906.9M | ||
| Q3 24 | $370.8M | $878.9M | ||
| Q2 24 | $394.8M | $905.4M |
| Q1 26 | $5.7B | $2.4B | ||
| Q4 25 | $5.7B | $2.5B | ||
| Q3 25 | $5.5B | $2.4B | ||
| Q2 25 | $4.4B | $2.5B | ||
| Q1 25 | $4.1B | $2.5B | ||
| Q4 24 | $2.4B | $2.5B | ||
| Q3 24 | $2.4B | $2.5B | ||
| Q2 24 | $2.5B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | 176.99× | 1.34× | ||
| Q3 25 | 20.59× | 1.44× | ||
| Q2 25 | 8.21× | 1.39× | ||
| Q1 25 | 5.79× | 1.49× | ||
| Q4 24 | 7.84× | — | ||
| Q3 24 | 4.14× | — | ||
| Q2 24 | 3.94× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.4M | $293.2M |
| Free Cash FlowOCF − Capex | — | $209.9M |
| FCF MarginFCF / Revenue | — | 60.6% |
| Capex IntensityCapex / Revenue | — | 9.5% |
| Cash ConversionOCF / Net Profit | — | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | — | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-69.4M | $293.2M | ||
| Q4 25 | $-2.8M | $93.6M | ||
| Q3 25 | $-24.4M | $111.3M | ||
| Q2 25 | $-5.2M | $17.4M | ||
| Q1 25 | $-85.7M | $116.6M | ||
| Q4 24 | $-8.1M | $43.8M | ||
| Q3 24 | $14.2M | $48.8M | ||
| Q2 24 | $-17.6M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | $-68.6M | $87.2M | ||
| Q3 25 | $-90.7M | $106.3M | ||
| Q2 25 | $-87.5M | $13.6M | ||
| Q1 25 | $-151.7M | $100.9M | ||
| Q4 24 | $-34.3M | $35.2M | ||
| Q3 24 | $-11.7M | $39.4M | ||
| Q2 24 | $-32.1M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | -47.8% | 25.7% | ||
| Q3 25 | -64.5% | 32.5% | ||
| Q2 25 | -71.6% | 4.2% | ||
| Q1 25 | -157.7% | 30.5% | ||
| Q4 24 | -42.4% | 10.1% | ||
| Q3 24 | -14.0% | 11.4% | ||
| Q2 24 | -37.9% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | 45.9% | 1.9% | ||
| Q3 25 | 47.2% | 1.5% | ||
| Q2 25 | 67.3% | 1.2% | ||
| Q1 25 | 68.6% | 4.7% | ||
| Q4 24 | 32.5% | 2.5% | ||
| Q3 24 | 31.1% | 2.7% | ||
| Q2 24 | 17.2% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | — | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | -0.71× | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | — | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FIP
Segment breakdown not available.
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
